10月22日，礼来盘中上涨3.06%，报1309.605美元/股，成交额10.48亿美元。
消息面上，市场正提前交易其财报预期改善。公司将于10月29日披露最新业绩，市场一致预期本季度营收约225.92亿美元，同比增长41.06%，调整后每股收益约6.94美元；同时，机构近期将目标价上调至1397美元，并维持买入评级。
此外，机构调研显示，礼来口服GLP-1药物Foundayo目前占口服GLP-1新增处方的27%，后续仍有提升空间，且Zepbound产品结构改善有望支撑下半年价格表现，强化了市场对其核心减重管线放量的预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments